Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,280 across all filing types
Latest filing 2024-11-22 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
山西香雪医药有限公司股东全部权益价值资产评估报告
Audit Report / Information Classification · 95% confidence The document is an asset valuation report prepared by an asset appraisal company for Shanxi Xiangxue Pharmaceutical Co., Ltd. It is titled as an "Asset Evaluation Report" and details the valuation of the entire equity of the company as of a specific valuation date (September 30, 2024). The report includes detailed sections such as the purpose of the evaluation, the scope, valuation methods, legal and regulatory bases, and detailed financial and asset data. It is not a financial report like an annual or interim report, nor is it an announcement or certification. It is a standalone asset appraisal report related to a shareholder equity transfer. This fits the category of an Audit Report / Information (AR), which includes standalone audit or valuation reports and applied accounting principles, excluding full annual reports. Therefore, the correct classification is AR with high confidence. 9M 2024
2024-11-22 Chinese
股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations and related risk disclosures by Guangzhou Xiangxue Pharmaceutical Co., Ltd. It includes details about regulatory investigations, litigation, stock pledges, and clarifications on disclosed information. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure to inform investors about unusual market activity and company status. It is not an annual report, audit report, earnings release, or any detailed financial report. The document is a regulatory announcement about stock trading abnormalities and related risks, fitting the category of Regulatory Filings (RNS). The document length is 3714 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-10-29 Chinese
第九届监事会第十六次会议决议公告
Report Publication Announcement Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the approval of the company's 2024 third quarter report. It states that the Supervisory Board has reviewed and approved the report and confirms its accuracy and compliance. However, the document itself does not contain the actual financial data or the full report; it refers readers to the full 2024 third quarter report disclosed on an external website (Juchao). The document length is short (631 characters) and serves as an announcement of the approval and availability of the report rather than the report itself. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR).
2024-10-25 Chinese
第九届董事会第二十三次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. It reports the approval of the company's 2024 third quarter report during the 23rd meeting of the 9th board. The text states that the report's content is true and accurate and refers readers to the full 2024 third quarter report disclosed on an external website (Juchao). The document itself does not contain the actual financial statements or substantive financial data but is an announcement of the board's approval of the report. The document length is short (686 characters), and it serves as a formal announcement of the approval and availability of the quarterly report rather than the report itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than an Interim/Quarterly Report (IR) or Report Publication Announcement (RPA) because it includes board resolution details and voting results, which are typical for regulatory filings.
2024-10-25 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 98% confidence The document is titled "广州市香雪制药股份有限公司2024 年第三季度报告" which translates to "Guangzhou Xiangxue Pharmaceutical Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the third quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It is not an announcement or a brief summary but a full financial report. The document is not an annual report (10-K), nor an earnings release (ER) which would be shorter and less detailed. It is not a certification or regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). The document length (13,597 characters) supports it being a full report rather than a brief announcement. 9M 2024
2024-10-25 Chinese
关于公司及实际控制人收到中国证券监督管理委员会立案告知书的公告
Legal Proceedings Report Classification · 95% confidence The document is an official announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the receipt of a formal investigation notice (立案告知书) from the China Securities Regulatory Commission (CSRC) about suspected violations related to information disclosure. It states the company and actual controller are under investigation and commits to cooperate and disclose information as required. The document is short (593 characters) and serves as a regulatory announcement about legal proceedings rather than a detailed report or financial statement. It does not contain financial data, management discussion, or audit information. Therefore, it fits best under Legal Proceedings Report (LTR).
2024-09-30 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.